Published in PLoS One on July 22, 2013
Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int (2014) 0.98
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood (2014) 0.87
Eosinophils regulate peripheral B cell numbers in both mice and humans. J Immunol (2014) 0.86
Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches. PLoS One (2014) 0.82
Extracellular vesicles in hematological disorders. Rambam Maimonides Med J (2014) 0.81
Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. Biomed Res Int (2015) 0.79
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res (2014) 0.78
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Multiple myeloma. N Engl J Med (2011) 10.38
The eosinophil. Annu Rev Immunol (2006) 7.06
Basophils enhance immunological memory responses. Nat Immunol (2008) 3.35
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol (2011) 2.83
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood (2008) 2.44
Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol (2008) 2.38
The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol (2002) 1.99
Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med (2006) 1.87
Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood (2010) 1.63
Staying alive: regulation of plasma cell survival. Trends Immunol (2011) 1.52
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 1.39
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol (1992) 1.39
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood (2005) 1.35
Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia (1996) 1.33
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood (2003) 1.29
Basophils support the survival of plasma cells in mice. J Immunol (2010) 1.24
Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol (2012) 1.21
Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood (2008) 1.21
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol (2012) 1.12
Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res (1993) 1.11
Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol (2005) 1.04
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res (2012) 1.02
Response patterns of purified myeloma cells to hematopoietic growth factors. Blood (1989) 1.01
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc (1987) 1.00
Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J (2012) 0.96
Immunization induces activation of bone marrow eosinophils required for plasma cell survival. Eur J Immunol (2011) 0.95
Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma (2007) 0.94
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood (2001) 0.93
The long-term survival of plasma cells. Scand J Immunol (2011) 0.91
Multiple myeloma: improved outcomes with new therapeutic approaches. Curr Opin Support Palliat Care (2012) 0.90
Alternative cell types form a Multi-Component-Plasma-Cell-Niche. Immunol Lett (2011) 0.90
Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique. Br J Haematol (1986) 0.89
Lymphoproliferative disorders associated with hypereosinophilia. Semin Hematol (2012) 0.85
Plasma cell myeloma associated with eosinophilia. Am J Clin Pathol (1995) 0.81
Under one roof: The bone marrow survival niche for multiple myeloma and normal plasma cells. Oncoimmunology (2012) 0.79
Purification of functional eosinophils from human bone marrow. J Immunol Methods (2012) 0.78
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Increased risk of serious pneumococcal disease in patients with asthma. J Allergy Clin Immunol (2008) 2.97
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol (2008) 2.78
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 2.72
Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol (2012) 2.68
IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol (2011) 2.54
How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc (2005) 2.48
School examinations enhance airway inflammation to antigen challenge. Am J Respir Crit Care Med (2002) 2.41
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol (2011) 2.33
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol (2008) 2.29
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2003) 2.12
Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2012) 2.09
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med (2015) 2.08
The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. Int J Cancer (2012) 2.06
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood (2007) 2.04
Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. J Immunol (2009) 1.96
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma (2007) 1.92
IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol (2009) 1.92
Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol (2004) 1.84
Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol (2005) 1.84
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2010) 1.83
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood (2010) 1.80
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood (2010) 1.79
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood (2011) 1.73
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood (2004) 1.71
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood (2002) 1.70
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood (2006) 1.65
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol (2014) 1.65
Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol (2007) 1.63
Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol (2002) 1.63
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol (2010) 1.62
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma (2012) 1.61
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol (2014) 1.58
Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet (2003) 1.58
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope (2009) 1.54
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood (2013) 1.53
Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immunol (2004) 1.52
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol (2009) 1.51
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood (2006) 1.50
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol (2009) 1.48
Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. Cell Cycle (2010) 1.47
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood (2012) 1.46
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol (2012) 1.44
The involvement of glucocorticoids in psychological stress-induced exacerbations of experimental allergic asthma. Int Arch Allergy Immunol (2014) 1.43
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol (2014) 1.42
One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc (2012) 1.41
Increased numbers of eosinophils, rather than only etiology, predict histologic changes in patients with esophageal eosinophilia. Clin Gastroenterol Hepatol (2012) 1.40
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood (2009) 1.38
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol (2013) 1.35
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 1.34
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol (2013) 1.34
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.33
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol (2009) 1.33
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood (2007) 1.33
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol (2007) 1.32
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol (2006) 1.30
Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc (2008) 1.30
Cigarette smoke-induced oxidative stress suppresses generation of dendritic cell IL-12 and IL-23 through ERK-dependent pathways. J Immunol (2008) 1.29
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood (2003) 1.29
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer (2008) 1.29
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res (2005) 1.29
The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol (2008) 1.29
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer (2010) 1.28
AMN107: tightening the grip of imatinib. Cancer Cell (2005) 1.27
A role for BLyS in the activation of innate immune cells. Blood (2006) 1.27
Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis. J Allergy Clin Immunol (2005) 1.27
Asthma-related environmental fungus, Alternaria, activates dendritic cells and produces potent Th2 adjuvant activity. J Immunol (2009) 1.26
Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer (2009) 1.24
Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol (2008) 1.24
MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol (2005) 1.23
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer (2012) 1.22
Lineage(-)Sca1+c-Kit(-)CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J Immunol (2011) 1.22
Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis. Am J Gastroenterol (2009) 1.21
Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood (2008) 1.21
B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol (2008) 1.21